Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The More Life CompanyTMLCF 3-Year EBITDA Growth Rate is 26.30% as of Mar. 2026, which is 18% below its 10-year median of 32.00. The stock has 3 warning signs investors should review. Among 808 Drug Manufacturers companies, The More Life Company ranks better than 75.5% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 26.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 28.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of The More Life Company was 44.80% per year. The lowest was 26.30% per year. And the median was 32.00% per year.
The More Life Company (OTCPK:TMLCF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
The More Life Company 3-Year EBITDA Growth Rate Related Terms
TMLCF vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, The More Life Company's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The More Life Company 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, The More Life Company's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where The More Life Company's 3-Year EBITDA Growth Rate falls into.
The More Life Company 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 26.30% mean?
The More Life Company (TMLCF) has a 3-Year EBITDA Growth Rate of 26.30% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for The More Life Company and its competitors. This is 18% below median its historical median of 32.00. Over the past decade, The More Life Company's 3-Year EBITDA Growth Rate has ranged from 26.30 to 44.80. According to the industry distribution chart, The More Life Company ranks #198 out of 808 companies in the Drug Manufacturers industry, placing it in the top 24.5%.
Is The More Life Company's 3-Year EBITDA Growth Rate too high?
The More Life Company's current 3-Year EBITDA Growth Rate of 26.30% is 18% below median its 10-year median of 32.00. Over the past 10 years, this metric has ranged from a low of 26.30 to a high of 44.80. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. The More Life Company's value of 26.30% is 198.9% above this industry median. Based on the distribution chart, The More Life Company ranks #198 out of 808 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does The More Life Company's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, The More Life Company ranks #198 out of 808 companies for 3-Year EBITDA Growth Rate. This places The More Life Company in the top 25% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.80. The More Life Company's value of 26.30% is 198.9% above this benchmark. Historically, The More Life Company's own 3-Year EBITDA Growth Rate has ranged from 26.30 to 44.80 over the past decade. While the company's 10-year median is 32.00 vs. the industry median of 8.80, The More Life Company has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The More Life Company's current 3-Year EBITDA Growth Rate of 26.30% is 198.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for The More Life Company and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The More Life Company's current 3-Year EBITDA Growth Rate is 26.30%, which is 18% below median its own 10-year median of 32.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The More Life Company stock overvalued right now?
The More Life Company (TMLCF) has a current 3-Year EBITDA Growth Rate of 26.30%. The current 3-Year EBITDA Growth Rate is 26.30%, which is 18% below median its 10-year median of 32.00 and 198.9% above the Drug Manufacturers industry median of 8.80. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For The More Life Company (TMLCF), the current 3-Year EBITDA Growth Rate is 26.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mountain Valley MD Holdings Inc is a Canada-based company. The firm, along with its subsidiaries, is engaged in implementing its Quicksome oral delivery technologies across a variety of molecules in nutraceutical, vaccine, and pharmaceutical drug applications. The company actively invests in and collaborates on pioneering biotechnologies that have the potential to revolutionize the human health and wellness landscape, drive sustainable increases in plant yields and agricultural farming practices, and broadly support animal husbandry health. The Company is a biotech company focused on advancing solutions to optimize human, animal, and plant health.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TMLCF has been successfully added to your 
